

Beatriz Silva Lima

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7617391/publications.pdf>

Version: 2024-02-01

32
papers

1,759
citations

361296

20
h-index

360920

35
g-index

38
all docs

38
docs citations

38
times ranked

2755
citing authors

#	ARTICLE	IF	CITATIONS
1	Applying 'omics technologies in chemicals risk assessment: Report of an ECETOC workshop. Regulatory Toxicology and Pharmacology, 2017, 91, S3-S13.	1.3	102
2	Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 110, 76-84.	2.0	46
3	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. Hepatology, 2017, 65, 710-721.	3.6	54
4	Evaluation of Marine Microalga <i>Diatronema vlkianum</i> Biomass Fatty Acid Assimilation in Wistar Rats. Molecules, 2017, 22, 1097.	1.7	8
5	Chronic Hyperglycemia Modulates Rat Osteoporotic Cortical Bone Microarchitecture into Less Fragile Structures. International Journal of Endocrinology, 2017, 2017, 1-9.	0.6	9
6	Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties. Critical Reviews in Toxicology, 2016, 46, 587-614.	1.9	30
7	The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?. Multiple Sclerosis Journal, 2016, 22, 47-59.	1.4	8
8	Total phenolic content, antioxidant activity and pre-clinical safety evaluation of an <i>Anacardium occidentale</i> stem bark Portuguese hypoglycemic traditional herbal preparation. Industrial Crops and Products, 2016, 82, 171-178.	2.5	23
9	Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discovery Today, 2015, 20, 483-490.	3.2	22
10	Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products. European Journal of Pharmacology, 2015, 759, 51-62.	1.7	24
11	Oral supplementation with fish oil reduces dryness and pruritus in the acetone-induced dry skin rat model. Journal of Dermatological Science, 2015, 79, 298-304.	1.0	28
12	Anti-inflammatory Effect of Rosmarinic Acid and an Extract of <i>Rosmarinus officinalis</i> in Rat Models of Local and Systemic Inflammation. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 398-413.	1.2	193
13	Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology, 2014, 70, 413-429.	1.3	22
14	Sales of antibiotics for veterinary use in Portugal between 2006 and 2009. International Journal of Antimicrobial Agents, 2014, 44, 567-568.	1.1	1
15	White Paper on How to Go Forward with Cell-Based Advanced Therapies in Europe. Tissue Engineering - Part A, 2014, 20, 2549-2554.	1.6	27
16	Insights on the safety of carotenogenic <i>Chlorella vulgaris</i> in rodents. Algal Research, 2013, 2, 409-415.	2.4	14
17	Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine, 2013, 8, 849-856.	1.7	122
18	Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs, 2013, 5, 810-816.	2.6	104

#	ARTICLE	IF	CITATIONS
19	Scientific considerations for complex drugs in light of established and emerging regulatory guidance. <i>Annals of the New York Academy of Sciences</i> , 2012, 1276, 26-36.	1.8	32
20	Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2011, 92, n/a-n/a.	1.4	5
21	Value of juvenile animal studies. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2011, 92, 292-303.	1.4	20
22	The European and American Use of Exploratory Approaches for First-in-Human Studies. <i>Clinical and Translational Science</i> , 2010, 3, 38-41.	1.5	2
23	Renal biomarker qualification submission: a dialog between the FDA-EMA and Predictive Safety Testing Consortium. <i>Nature Biotechnology</i> , 2010, 28, 455-462.	9.4	355
24	Towards consensus practices to qualify safety biomarkers for use in early drug development. <i>Nature Biotechnology</i> , 2010, 28, 446-454.	9.4	113
25	Challenges with advanced therapy medicinal products and how to meet them. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 195-201.	21.5	191
26	Supplementation of the Diet of Haemodialysis Patients with Portuguese Canned Sardines and Evaluation of ω 3 Fatty Acid Level in Erythrocyte Phospholipids. <i>Journal of Aquatic Food Product Technology</i> , 2004, 13, 61-68.	0.6	3
27	Phenylephrine Induces Endogenous Noradrenaline Release in the Rat Vas deferens through Nitric Oxide Synthase Pathway. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2003, 93, 191-196.	0.0	1
28	Alternatives Models in Carcinogenicity Testing – A European Perspective. <i>Toxicologic Pathology</i> , 2002, 30, 157-159.	0.9	7
29	Effect of a Supplemented Diet with Canned Sardine on the Lipid Fraction of Human Plasma and Erythrocytes. <i>Journal of Aquatic Food Product Technology</i> , 2002, 11, 177-185.	0.6	14
30	Nitric Oxide Synthase/Guanylate Cyclase Pathway Modulates the Rat Vas Deferens Contractility Induced by Phenylephrine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 91, 179-184.	0.0	3
31	Carcinogenicity Testing of Pharmaceuticals in the European Union: A Workshop Report. <i>Drug Information Journal</i> , 2000, 34, 821-828.	0.5	8
32	Mechanisms of Nongenotoxic Carcinogenesis and Assessment of the Human Hazard. <i>Regulatory Toxicology and Pharmacology</i> , 2000, 32, 135-143.	1.3	90